NovoCure (NVCR) Cost of Revenue (2014 - 2026)

NovoCure has disclosed Cost of Revenue across 13 years of filings, most recently posting $41.1 million for Q2 2026.

• In Q2 2026, Cost of Revenue fell 0.88% year-over-year to $41.1 million; the TTM figure through Jun 2026 stood at $166.9 million (up 12.15% YoY), while the FY2025 annual figure was $166.9 million, up 21.65% from the prior year.
• Cost of Revenue came in at $41.1 million for Q2 2026 at NovoCure, up from $38.9 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $44.7 million in Q3 2025 to a low of $27.7 million in Q1 2022.
• Average Cost of Revenue over 5 years is $34.8 million, with a median of $33.9 million recorded in 2023.
• Year-over-year, Cost of Revenue declined 2.69% in 2022 and grew 26.45% in 2025.
• Over 5 years, Cost of Revenue stood at $28.9 million in 2022, then climbed by 12.7% to $32.6 million in 2023, then advanced by 2.8% to $33.5 million in 2024, then advanced by 25.97% to $42.2 million in 2025, then dropped by 2.49% to $41.1 million in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $41.1 million in Q2 2026, $38.9 million in Q1 2026, and $42.2 million in Q4 2025.